These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22594690)

  • 1. A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779.
    Dugan BJ; Gingrich DE; Mesaros EF; Milkiewicz KL; Curry MA; Zulli AL; Dobrzanski P; Serdikoff C; Jan M; Angeles TS; Albom MS; Mason JL; Aimone LD; Meyer SL; Huang Z; Wells-Knecht KJ; Ator MA; Ruggeri BA; Dorsey BD
    J Med Chem; 2012 Jun; 55(11):5243-54. PubMed ID: 22594690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics.
    Oguro Y; Cary DR; Miyamoto N; Tawada M; Iwata H; Miki H; Hori A; Imamura S
    Bioorg Med Chem; 2013 Aug; 21(15):4714-29. PubMed ID: 23755884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors.
    Siu M; Pastor R; Liu W; Barrett K; Berry M; Blair WS; Chang C; Chen JZ; Eigenbrot C; Ghilardi N; Gibbons P; He H; Hurley CA; Kenny JR; Cyrus Khojasteh S; Le H; Lee L; Lyssikatos JP; Magnuson S; Pulk R; Tsui V; Ultsch M; Xiao Y; Zhu BY; Sampath D
    Bioorg Med Chem Lett; 2013 Sep; 23(17):5014-21. PubMed ID: 23870430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.
    Zak M; Mendonca R; Balazs M; Barrett K; Bergeron P; Blair WS; Chang C; Deshmukh G; Devoss J; Dragovich PS; Eigenbrot C; Ghilardi N; Gibbons P; Gradl S; Hamman C; Hanan EJ; Harstad E; Hewitt PR; Hurley CA; Jin T; Johnson A; Johnson T; Kenny JR; Koehler MF; Bir Kohli P; Kulagowski JJ; Labadie S; Liao J; Liimatta M; Lin Z; Lupardus PJ; Maxey RJ; Murray JM; Pulk R; Rodriguez M; Savage S; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward SI; Xiao L; Xiao Y
    J Med Chem; 2012 Jul; 55(13):6176-93. PubMed ID: 22698084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
    Dymock BW; See CS
    Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.
    Lim J; Taoka B; Otte RD; Spencer K; Dinsmore CJ; Altman MD; Chan G; Rosenstein C; Sharma S; Su HP; Szewczak AA; Xu L; Yin H; Zugay-Murphy J; Marshall CG; Young JR
    J Med Chem; 2011 Oct; 54(20):7334-49. PubMed ID: 21942426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.
    Forsyth T; Kearney PC; Kim BG; Johnson HW; Aay N; Arcalas A; Brown DS; Chan V; Chen J; Du H; Epshteyn S; Galan AA; Huynh TP; Ibrahim MA; Kane B; Koltun ES; Mann G; Meyr LE; Lee MS; Lewis GL; Noguchi RT; Pack M; Ridgway BH; Shi X; Takeuchi CS; Zu P; Leahy JW; Nuss JM; Aoyama R; Engst S; Gendreau SB; Kassees R; Li J; Lin SH; Martini JF; Stout T; Tong P; Woolfrey J; Zhang W; Yu P
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7653-8. PubMed ID: 23127890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
    Cee VJ; Schenkel LB; Hodous BL; Deak HL; Nguyen HN; Olivieri PR; Romero K; Bak A; Be X; Bellon S; Bush TL; Cheng AC; Chung G; Coats S; Eden PM; Hanestad K; Gallant PL; Gu Y; Huang X; Kendall RL; Lin MH; Morrison MJ; Patel VF; Radinsky R; Rose PE; Ross S; Sun JR; Tang J; Zhao H; Payton M; Geuns-Meyer SD
    J Med Chem; 2010 Sep; 53(17):6368-77. PubMed ID: 20684549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors.
    Su Q; Ioannidis S; Chuaqui C; Almeida L; Alimzhanov M; Bebernitz G; Bell K; Block M; Howard T; Huang S; Huszar D; Read JA; Rivard Costa C; Shi J; Su M; Ye M; Zinda M
    J Med Chem; 2014 Jan; 57(1):144-58. PubMed ID: 24359159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.
    Zak M; Hurley CA; Ward SI; Bergeron P; Barrett K; Balazs M; Blair WS; Bull R; Chakravarty P; Chang C; Crackett P; Deshmukh G; DeVoss J; Dragovich PS; Eigenbrot C; Ellwood C; Gaines S; Ghilardi N; Gibbons P; Gradl S; Gribling P; Hamman C; Harstad E; Hewitt P; Johnson A; Johnson T; Kenny JR; Koehler MF; Bir Kohli P; Labadie S; Lee WP; Liao J; Liimatta M; Mendonca R; Narukulla R; Pulk R; Reeve A; Savage S; Shia S; Steffek M; Ubhayakar S; van Abbema A; Aliagas I; Avitabile-Woo B; Xiao Y; Yang J; Kulagowski JJ
    J Med Chem; 2013 Jun; 56(11):4764-85. PubMed ID: 23659214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
    Brasca MG; Nesi M; Avanzi N; Ballinari D; Bandiera T; Bertrand J; Bindi S; Canevari G; Carenzi D; Casero D; Ceriani L; Ciomei M; Cirla A; Colombo M; Cribioli S; Cristiani C; Della Vedova F; Fachin G; Fasolini M; Felder ER; Galvani A; Isacchi A; Mirizzi D; Motto I; Panzeri A; Pesenti E; Vianello P; Gnocchi P; Donati D
    Bioorg Med Chem; 2014 Sep; 22(17):4998-5012. PubMed ID: 25009002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.
    Lu LD; Stump KL; Wallace NH; Dobrzanski P; Serdikoff C; Gingrich DE; Dugan BJ; Angeles TS; Albom MS; Mason JL; Ator MA; Dorsey BD; Ruggeri BA; Seavey MM
    J Immunol; 2011 Oct; 187(7):3840-53. PubMed ID: 21880982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.
    Zhu GD; Gandhi VB; Gong J; Thomas S; Woods KW; Song X; Li T; Diebold RB; Luo Y; Liu X; Guan R; Klinghofer V; Johnson EF; Bouska J; Olson A; Marsh KC; Stoll VS; Mamo M; Polakowski J; Campbell TJ; Martin RL; Gintant GA; Penning TD; Li Q; Rosenberg SH; Giranda VL
    J Med Chem; 2007 Jun; 50(13):2990-3003. PubMed ID: 17523610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.
    Wittman M; Carboni J; Attar R; Balasubramanian B; Balimane P; Brassil P; Beaulieu F; Chang C; Clarke W; Dell J; Eummer J; Frennesson D; Gottardis M; Greer A; Hansel S; Hurlburt W; Jacobson B; Krishnananthan S; Lee FY; Li A; Lin TA; Liu P; Ouellet C; Sang X; Saulnier MG; Stoffan K; Sun Y; Velaparthi U; Wong H; Yang Z; Zimmermann K; Zoeckler M; Vyas D
    J Med Chem; 2005 Sep; 48(18):5639-43. PubMed ID: 16134929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and anticancer activity evaluation of a series of [1,2,4]triazolo[1,5-a]pyridinylpyridines in vitro and in vivo.
    Wang XM; Xu J; Li YP; Li H; Jiang CS; Yang GD; Lu SM; Zhang SQ
    Eur J Med Chem; 2013 Sep; 67():243-51. PubMed ID: 23871904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.
    William AD; Lee AC; Blanchard S; Poulsen A; Teo EL; Nagaraj H; Tan E; Chen D; Williams M; Sun ET; Goh KC; Ong WC; Goh SK; Hart S; Jayaraman R; Pasha MK; Ethirajulu K; Wood JM; Dymock BW
    J Med Chem; 2011 Jul; 54(13):4638-58. PubMed ID: 21604762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.
    Kulagowski JJ; Blair W; Bull RJ; Chang C; Deshmukh G; Dyke HJ; Eigenbrot C; Ghilardi N; Gibbons P; Harrison TK; Hewitt PR; Liimatta M; Hurley CA; Johnson A; Johnson T; Kenny JR; Bir Kohli P; Maxey RJ; Mendonca R; Mortara K; Murray J; Narukulla R; Shia S; Steffek M; Ubhayakar S; Ultsch M; van Abbema A; Ward SI; Waszkowycz B; Zak M
    J Med Chem; 2012 Jun; 55(12):5901-21. PubMed ID: 22591402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.
    Schenkel LB; Huang X; Cheng A; Deak HL; Doherty E; Emkey R; Gu Y; Gunaydin H; Kim JL; Lee J; Loberg R; Olivieri P; Pistillo J; Tang J; Wan Q; Wang HL; Wang SW; Wells MC; Wu B; Yu V; Liu L; Geuns-Meyer S
    J Med Chem; 2011 Dec; 54(24):8440-50. PubMed ID: 22087750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and optimization of a series of 3-(3-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amines: orally bioavailable, selective, and potent ATP-independent Akt inhibitors.
    Ashwell MA; Lapierre JM; Brassard C; Bresciano K; Bull C; Cornell-Kennon S; Eathiraj S; France DS; Hall T; Hill J; Kelleher E; Khanapurkar S; Kizer D; Koerner S; Link J; Liu Y; Makhija S; Moussa M; Namdev N; Nguyen K; Nicewonger R; Palma R; Szwaya J; Tandon M; Uppalapati U; Vensel D; Volak LP; Volckova E; Westlund N; Wu H; Yang RY; Chan TC
    J Med Chem; 2012 Jun; 55(11):5291-310. PubMed ID: 22533986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease.
    Sunose M; Bell K; Ellard K; Bergamini G; Neubauer G; Werner T; Ramsden N
    Bioorg Med Chem Lett; 2012 Jul; 22(14):4613-8. PubMed ID: 22726925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.